Merck’s and Ridgeback’s Oral Treatment for COVID-19 Gets Its First Regulatory Approval

Merck’s and Ridgeback Biotherapeutics’ oral COVID-19 medication got its first green light from a regulatory body this week when the UK approved it, making it the first oral antiviral medicine authorized for the treatment of COVID-19. The companies still await authorization from the FDA, which could come early next month.
Source: Drug Industry Daily